Posted by Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
– Company’s pivotal Phase 3 study, TransportNPC™, ongoing with global site activation and patient enrollment underway
– Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC
– Trappsol® Cyclo™ demonstrates acceptable safety profile, administered intravenously, for more than 2 years
The results of this and the clinical trial aiming to treat Alzheimer disease were presented at the Virtual Investor 2022 Top Picks Conference. See the presentation here: https://cyclotherapeutics.com/wp-content/uploads/2022/01/CYTH_Investor-Presentation_January-22.pdf